Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer

A. David McCollum; Steven C. Burrell; Robert I. Haddad; Charles M. Norris; Roy B. Tishler; Mary Ann Case; Marshall R. Posner; Annick D. Van Den Abbeele

doi:10.1002/hed.20080

Positron emission tomography with ¹⁸F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer

A. David McCollum, Steven C. Burrell, Robert I. Haddad, Charles M. Norris, Roy B. Tishler, Mary Ann Case, Marshall R. Posner, Annick D. Van Den Abbeele

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Abstract

Background. Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). We studied the accuracy of positron emission tomography (PET) with ¹⁸F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT). Methods. Forty patients with advanced SCCHN were treated with ICT followed by CRT. FDG-PET imaging was performed to assess for residual cancer at the primary site and in nodal metastases. Two nuclear medicine physicians interpreted PET scans in random sequence. Test characteristics were calculated with pathologic analysis or clinical recurrence as the standard. Results. After induction chemotherapy, PET imaging had a sensitivity of 100% and specificity of 65% for detecting persistent disease at the primary tumor site. After ICT and CRT were completed, the sensitivity and specificity of PET imaging were 67% and 53%, respectively, for detecting occult disease in cervical lymph nodes. Conclusions. FDG-PET imaging showed some correlation with pathologic response after ICT and CRT in patients with advanced SCCHN. The use of FDG-PET warrants further investigation in this setting.

Original language	English
Pages (from-to)	890-896
Number of pages	7
Journal	Head and Neck
Volume	26
Issue number	10
DOIs	https://doi.org/10.1002/hed.20080
State	Published - Oct 2004
Externally published	Yes

Keywords

Chemoradiotherapy
Head and neck cancer
Organ-preservation
Positron emission tomography
Residual disease

Access to Document

10.1002/hed.20080

Cite this

McCollum, A. D., Burrell, S. C., Haddad, R. I., Norris, C. M., Tishler, R. B., Case, M. A., Posner, M. R., & Van Den Abbeele, A. D. (2004). Positron emission tomography with ¹⁸F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head and Neck, 26(10), 890-896. https://doi.org/10.1002/hed.20080

@article{8c17a6553b3c4f3c924d90867c120380,

title = "Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer",

abstract = "Background. Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). We studied the accuracy of positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT). Methods. Forty patients with advanced SCCHN were treated with ICT followed by CRT. FDG-PET imaging was performed to assess for residual cancer at the primary site and in nodal metastases. Two nuclear medicine physicians interpreted PET scans in random sequence. Test characteristics were calculated with pathologic analysis or clinical recurrence as the standard. Results. After induction chemotherapy, PET imaging had a sensitivity of 100% and specificity of 65% for detecting persistent disease at the primary tumor site. After ICT and CRT were completed, the sensitivity and specificity of PET imaging were 67% and 53%, respectively, for detecting occult disease in cervical lymph nodes. Conclusions. FDG-PET imaging showed some correlation with pathologic response after ICT and CRT in patients with advanced SCCHN. The use of FDG-PET warrants further investigation in this setting.",

keywords = "Chemoradiotherapy, Head and neck cancer, Organ-preservation, Positron emission tomography, Residual disease",

author = "McCollum, {A. David} and Burrell, {Steven C.} and Haddad, {Robert I.} and Norris, {Charles M.} and Tishler, {Roy B.} and Case, {Mary Ann} and Posner, {Marshall R.} and {Van Den Abbeele}, {Annick D.}",

year = "2004",

month = oct,

doi = "10.1002/hed.20080",

language = "English",

volume = "26",

pages = "890--896",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer

AU - McCollum, A. David

AU - Burrell, Steven C.

AU - Haddad, Robert I.

AU - Norris, Charles M.

AU - Tishler, Roy B.

AU - Case, Mary Ann

AU - Posner, Marshall R.

AU - Van Den Abbeele, Annick D.

PY - 2004/10

Y1 - 2004/10

N2 - Background. Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). We studied the accuracy of positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT). Methods. Forty patients with advanced SCCHN were treated with ICT followed by CRT. FDG-PET imaging was performed to assess for residual cancer at the primary site and in nodal metastases. Two nuclear medicine physicians interpreted PET scans in random sequence. Test characteristics were calculated with pathologic analysis or clinical recurrence as the standard. Results. After induction chemotherapy, PET imaging had a sensitivity of 100% and specificity of 65% for detecting persistent disease at the primary tumor site. After ICT and CRT were completed, the sensitivity and specificity of PET imaging were 67% and 53%, respectively, for detecting occult disease in cervical lymph nodes. Conclusions. FDG-PET imaging showed some correlation with pathologic response after ICT and CRT in patients with advanced SCCHN. The use of FDG-PET warrants further investigation in this setting.

AB - Background. Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). We studied the accuracy of positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT). Methods. Forty patients with advanced SCCHN were treated with ICT followed by CRT. FDG-PET imaging was performed to assess for residual cancer at the primary site and in nodal metastases. Two nuclear medicine physicians interpreted PET scans in random sequence. Test characteristics were calculated with pathologic analysis or clinical recurrence as the standard. Results. After induction chemotherapy, PET imaging had a sensitivity of 100% and specificity of 65% for detecting persistent disease at the primary tumor site. After ICT and CRT were completed, the sensitivity and specificity of PET imaging were 67% and 53%, respectively, for detecting occult disease in cervical lymph nodes. Conclusions. FDG-PET imaging showed some correlation with pathologic response after ICT and CRT in patients with advanced SCCHN. The use of FDG-PET warrants further investigation in this setting.

KW - Chemoradiotherapy

KW - Head and neck cancer

KW - Organ-preservation

KW - Positron emission tomography

KW - Residual disease

UR - http://www.scopus.com/inward/record.url?scp=4644337369&partnerID=8YFLogxK

U2 - 10.1002/hed.20080

DO - 10.1002/hed.20080

M3 - Article

C2 - 15390197

AN - SCOPUS:4644337369

SN - 1043-3074

VL - 26

SP - 890

EP - 896

JO - Head and Neck

JF - Head and Neck

IS - 10

ER -